Cytokinetics (CYTK) awards 151-share fully vested grant to director

Rhea-AI Filing Summary

Kaye Edward M. MD reported acquisition or exercise transactions in this Form 4 filing.

CYTOKINETICS INC director Edward M. Kaye, MD received a grant of 151 shares of common stock on July 15, 2026 under the Cytokinetics Equity in lieu of Cash Retainer Program. The shares were fully vested at grant, bringing his direct holdings to 10,434 common shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kaye Edward M. MD

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	151	$82.62	$12K

Holdings After Transaction: Common Stock — 10,434 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 151.0000 shares Grant reference price: $82.6200 per share Shares owned after grant: 10434.0000 shares

3 metrics

Shares granted 151.0000 shares Common stock awarded on July 15, 2026

Grant reference price $82.6200 per share Valuation used for the stock grant

Shares owned after grant 10434.0000 shares Direct common stock holding following the award

Key Terms

Cytokinetics Equity in lieu of Cash Retainer Program, fully vested, Common Stock

3 terms

Cytokinetics Equity in lieu of Cash Retainer Program financial

"Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program."

fully vested financial

"Shares are fully vested at the time of grant."

Common Stock financial

"Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/16/2026 - 04:33 PM Accepted by SEC EDGAR 07/16/2026 - 04:32 PM Learn about SEC filing dates

FAQ

What insider transaction did CYTK director Edward M. Kaye report on this Form 4?

Edward M. Kaye, MD reported receiving a grant of 151 shares of Cytokinetics common stock. The award was made under the company’s Equity in lieu of Cash Retainer Program and represents director compensation rather than an open-market stock purchase.

What price and value were used for the CYTK stock grant to Edward M. Kaye?

The 151 Cytokinetics shares were referenced at $82.6200 per share. This price reflects the valuation used for the equity retainer grant and does not represent an open-market trade by the director.

How many CYTK shares does Edward M. Kaye own after this Form 4 transaction?

Following the grant, Edward M. Kaye directly holds 10,434 shares of Cytokinetics common stock. This figure reflects his updated beneficial ownership after the fully vested equity retainer award reported in the Form 4.

What is the Cytokinetics Equity in lieu of Cash Retainer Program mentioned in the CYTK Form 4?

The filing states that the shares were granted under the Cytokinetics Equity in lieu of Cash Retainer Program. Under this program, directors receive company stock instead of a cash retainer as part of their board compensation.

Are the CYTK shares granted to Edward M. Kaye subject to vesting conditions?

According to the footnote, the shares of Cytokinetics common stock granted to Edward M. Kaye are fully vested at the time of grant. This means there are no ongoing vesting requirements attached to this particular equity award.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaye Edward M. MD

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		A(1)		151	A	$82.62	10,434	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.

	/s/ John Faurescu, attorney-in-fact for Dr. Kaye	07/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)